A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results